Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature

With the advent of potent second-line anti-androgen therapy, we and others have observed an increased incidence of androgen receptor (AR)-null small cell or neuroendocrine prostate cancer (SCNPC) in metastatic castration-resistant prostate cancer (mCRPC). Our study was designed to determine the effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Labrecque, Mark P., Brown, Lisha G., Coleman, Ilsa M., Nguyen, Holly M., Lin, Daniel W., Corey, Eva, Nelson, Peter S., Morrissey, Colm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817027/
https://www.ncbi.nlm.nih.gov/pubmed/33471819
http://dx.doi.org/10.1371/journal.pone.0245602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817027/
https://www.ncbi.nlm.nih.gov/pubmed/33471819
http://dx.doi.org/10.1371/journal.pone.0245602

Ejemplares similares